08:00 , Nov 23, 2009 |  BC Week In Review  |  Clinical News

Exhale Drug-Eluting Stents: Phase III data

The double-blind, placebo-controlled, international Phase III EASE trial in 315 patients with emphysema or COPD showed that Exhale Drug-Eluting Stents missed the composite endpoint of improving forced vital capacity and modified Medical Research Council (mMRC)...
08:00 , Dec 8, 2008 |  BioCentury  |  Finance

Ebb & Flow

With capital markets tight, biotech companies are looking for non-dilutive ways to guarantee access to new funds should they need them. Last week, Micromet (NASDAQ:MITI) and Newron (SWX:NWRN) both secured equity agreements that provide them...
07:00 , Jun 6, 2005 |  BC Week In Review  |  Company News

Angiotech, Broncus deal

ANP granted Broncus a worldwide, non-exclusive license to use paclitaxel technology with Broncus' Exhale system to treat emphysema and other diseases related to chronic obstructive pulmonary disorder (COPD). ANP will receive an upfront payment and...